Reuters logo
BRIEF-FDA grants orphan drug designation for TRM-201 (rofecoxib) for treatment of hemophilic arthropathy
November 21, 2017 / 1:31 PM / a month ago

BRIEF-FDA grants orphan drug designation for TRM-201 (rofecoxib) for treatment of hemophilic arthropathy

Nov 21 (Reuters) - Tremeau Pharmaceuticals, Inc

* FDA grants orphan drug designation for TRM-201 (rofecoxib) for the treatment of hemophilic arthropathy

* FDA grants orphan drug designation for TRM-201 (rofecoxib) for the treatment of hemophilic arthropathy Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below